|
de la Torre R, Farre M, O Mathuna B, Roset PN, Pizarro N, Segura M, Torrens M, Ortuno J, Pujadas M, Cami J.
“MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers”.
Eur J Clin Pharmacol. 2005 Jul 23;Published on-line.
|
|
Abstract
No abstract provided; The report recounts a comparison across partiicpants enrolled in a randomized, placebo-controlled, double-blind study of two doses of 100 mg MDMA, with the second dose administered 24 h after the initial dose in 10 men (Farré et al. 2004). Assessing CYP2D6 function with dextromethorphan/dextorphan test established that 9 of 10 participants were "extensive metabolizers," and one was a "poor metabolizer." Subsequent assessment to detect the most common variations in the CYP2D6 gene detected 3 participants with at least one abnormal CYP2D6 gene, and found the poor metabolizer to have two abnormal CYP2D6 genes. Having abnormal CYP2D6 genes altered MDMA metabolism, with having two abnormal genes increasing MDMA AUC and decreasing HMMA AUC. The poor metabolizer with two abnormal CYP2D6 genes also had slightly higher body temperature than the extensive metabolizers. Blood levels of MDMA and metabolites were no longer significantly different across the different CYP2D6 genotypes after the second dose of MDMA. It appears that CYP2D6 function can alter plasma MDMA levels.
|
